SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F þ               Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):                     

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):                     

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o               No þ

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-                    .

 

 

QUARTERLY REPORT
Quarter Ended June 30, 2008

Currency of Presentation and Certain Defined Terms

     In this Quarterly Report, references to “$” or “dollars” or “U.S.$” or “U.S. dollars” are to the legal currency of the United States and references to “Rs.” or “rupees” or “Indian rupees” are to the legal currency of India. Our financial statements are presented in Indian rupees and are prepared in accordance with International Financial Reporting Standards. Convenience translation into U.S. dollars with respect to the unaudited condensed consolidated interim financial statements is also presented. References to a particular “fiscal” year are to our fiscal year ended March 31 of such year. References to “ADS” are to our American Depositary Shares, to the “FASB” are to the Financial Accounting Standards Board, to “SFAS” are to the Statements of Financial Accounting Standards, to “SAB” are to Staff Accounting Bulletin and to the “EITF” are to the Emerging Issues Task Force. All references to “IAS” are to the International Accounting Standards, to “IASB” are to the International Accounting Standards Board, to “IFRS” are to International Financial Reporting Standards, to “SIC” are to Standing Interpretations Committee and to “IFRIC” are to the International Financial Reporting Interpretations Committee.

     References to “U.S. FDA” are to the United States Food and Drug Administration, to “NDAs” are to New Drug Applications, and to “ANDAs” are to Abbreviated New Drug Applications.

     References to “U.S.” or “United States” are to the United States of America, its territories and its possessions. References to “India” are to the Republic of India. All references to “we,” “us,” “our,” “DRL,” “Dr. Reddy’s” or the “Company” shall mean Dr. Reddy’s Laboratories Limited and its subsidiaries. “Dr. Reddy’s” is a registered trademark of Dr. Reddy’s Laboratories Limited in India. Other trademarks or trade names used in this Quarterly Report are trademarks registered in the name of Dr. Reddy’s Laboratories Limited or are pending before the respective trademark registries.

     Except as otherwise stated in this report, all translations from Indian rupees to U.S. dollars are based on the noon buying rate in the City of New York on June 30, 2008 for cable transfers in Indian rupees as certified for customs purposes by the Federal Reserve Bank of New York, which was Rs.42.93 per U.S.$1.00. No representation is made that the Indian rupee amounts have been, could have been or could be converted into U.S. dollars at such a rate or any other rate. Any discrepancies in any table between totals and sums of the amounts listed are due to rounding.

     Information contained in our website, www.drreddys.com, is not part of this Quarterly Report and no portion of such information is incorporated herein.

Forward-Looking and Cautionary Statement

          IN ADDITION TO HISTORICAL INFORMATION, THIS QUARTERLY REPORT CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE REFLECTED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT MIGHT CAUSE SUCH A DIFFERENCE INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN THE SECTION ENTITLED “OPERATING AND FINANCIAL REVIEW” AND ELSEWHERE IN THIS REPORT. READERS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH REFLECT OUR ANALYSIS ONLY AS OF THE DATE HEREOF. IN ADDITION, READERS SHOULD CAREFULLY REVIEW THE INFORMATION IN OUR PERIODIC REPORTS AND OTHER DOCUMENTS FILED AND/OR FURNISHED WITH THE SECURITIES AND EXCHANGE COMMISSION (“SEC”) FROM TIME TO TIME.

TABLE OF CONTENTS

ITEM 1. FINANCIAL STATEMENTS			4
ITEM 2. OPERATING AND FINANCIAL REVIEW			45
ITEM 3. LIQUIDITY AND CAPITAL RESOURCES			51
ITEM 4. RECENT DEVELOPMENTS			53
ITEM 5. TREND INFORMATION			54
ITEM 6. EXHIBITS			56
SIGNATURES			57
EX 99.1: INDEPENDENT AUDITORS’ REPORT ON REVIEW OF UNAUDITED CONDENSED CONSOLIDATED       INTERIM FINANCIAL INFORMATION

				As of
Particulars		Note		June 30, 2008				June 30, 2008				March 31, 2008
				Convenience translation
				into U.S.$
Assets
Property, plant and equipment		9		U.S.$	449,480			Rs.	19,296,169			Rs.	16,765,432
Goodwill		10			429,571				18,441,471				16,997,288
Other intangible assets		11			444,794				19,094,986				16,755,508
Investment in equity accounted investees					5,558				238,587				237,054
Other investments					—				—				2,728
Other non-current assets					3,244				139,246				80,153
Total non-current assets					1,332,645				57,210,459				50,838,163
Inventories		12			303,817				13,042,846				11,132,830
Trade receivables, net of allowances					206,284				8,855,793				6,823,448
Other current assets					114,011				4,894,471				3,858,155
Other investments					76,125				3,268,062				4,753,580
Cash and cash equivalents		13			86,744				3,723,929				7,421,441
Total current assets					786,981				33,785,101				33,989,454
Total assets				U.S.$	2,119,626			Rs.	90,995,560			Rs.	84,827,617
Equity
Share capital				U.S.$	19,601			Rs.	841,487			Rs.	840,864
Share premium					468,397				20,108,278				20,036,473
Unrealized gain/(loss) on investments					15				633				(1,757	)
Foreign currency translation reserve					66,088				2,837,167				1,566,499
Share based payment reserve					15,723				674,999				709,006
Hedging reserve					(11,304	)			(485,299	)			(6,642	)
Equity shares held by controlled trust					(114	)			(4,882	)			(4,882	)
Retained earnings					589,857				25,322,546				24,211,253
Total equity				U.S.$	1,148,263			Rs.	49,294,929			Rs.	47,350,814
Liabilities
Long term loans and borrowings, excluding current portion		19		U.S.$	298,961			Rs.	12,834,397			Rs.	12,697,550
Provisions					4,016				172,390				122,901
Other non-current liabilities					10,007				429,598				323,378
Deferred tax liabilities					116,256				4,990,879				4,856,381
Total non-current liabilities					429,240				18,427,264				18,000,210
Bank overdraft		13			20,867				895,802				434,928
Short term loans and borrowings		19			67,099				2,880,570				4,427,781
Long term loans and borrowings, current portion		19			52,194				2,240,699				1,791,004
Trade payables					180,971				7,769,106				5,426,546
Provisions					27,804				1,193,611				626,999
Other current liabilities					193,188				8,293,579				6,769,335
Total current liabilities					542,124				23,273,367				19,476,593
Total liabilities				U.S.$	971,363			Rs.	41,700,631			Rs.	37,476,803
Total equity and liabilities				U.S.$	2,119,626			Rs.	90,995,560			Rs.	84,827,617

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM INCOME STATEMENTS
(in thousands, except share and per share data)

						Three months ended
Particulars		Note				June 30, 2008				June 30, 2008 *				June 30, 2007
						Convenience
						translation
						into U.S.$
Revenues						U.S.$	350,287			Rs.	15,037,803			Rs.	11,983,058
Cost of revenues							175,715				7,543,466				5,914,180
Gross profit						U.S.$	174,571			Rs.	7,494,337			Rs.	6,068,878
Selling, general and administrative expenses							118,457				5,085,351				3,581,305
Research and development expenses							24,460				1,050,070				806,278
Other expense/(income), net			14				5,616				241,104				(82,681	)
Total operating expenses, net						U.S.$	148,533			Rs.	6,376,525			Rs.	4,304,902
Results from operating activities							26,038				1,117,812				1,763,976
Finance income							7,454				320,013				576,672
Finance expense							(5,660	)			(242,983	)			(418,263	)
Finance income, net			15				1,794				77,030				158,409
Share of profit/(loss) of equity accounted investees, net of income tax							7				297				(4,028	)
Profit before income tax							27,839				1,195,139				1,918,357
Income tax expense			8				(1,953	)			(83,846	)			(321,715	)
Profit for the period						U.S.$	25,886			Rs.	1,111,293			Rs.	1,596,642
Attributable to:
Equity holders of the Company							25,886				1,111,293				1,599,665
Minority interest							—				—				(3,023	)
Profit for the period						U.S.$	25,886			Rs.	1,111,293			Rs.	1,596,642
Earnings per share			16
Basic earnings per share of Rs.5/- each						U.S.$	0.15			Rs.	6.61			Rs.	9.53
Diluted earnings per share of Rs.5/- each						U.S.$	0.15			Rs.	6.58			Rs.	9.48

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

														Unrealized
														gain/(loss) on other				Foreign currency				Share based
Particulars		Share capital								Share premium				investments				translation reserve				payment reserve
		Shares				Amount				Amount				Amount				Amount				Amount
Balance as of April 1, 2008			168,172,746			Rs.	840,864			Rs.	20,036,473			Rs.	(1,757	)		Rs.	1,566,499			Rs.	709,006
Issue of equity shares on exercise of options			124,637				623				71,805				—				—				(68,029	)
Share based payment expense			—				—				—				—				—				34,022
Profit for the period			—				—				—				—				—				—
Changes in fair value of investments, net of tax expense of Rs.2,474			—				—				—				2,390				—				—
Foreign exchange translation adjustments, net of tax expense of Rs.127,319			—				—				—				—				1,270,668				—
Effective portion of changes in fair value of cash flow hedges, net of tax benefit of Rs.246,471			—				—				—				—				—				—
Balance as of June 30, 2008			168,297,383			Rs.	841,487			Rs.	20,108,278			Rs.	633			Rs.	2,837,167			Rs.	674,999
Convenience translation into U.S. $						U.S. $	19,601			U.S. $	468,397			U.S. $	15			U.S. $	66,088			U.S. $	15,723
Balance as of April 1, 2007			167,912,180			Rs.	839,561			Rs.	19,908,837			Rs.	(125,182	)		Rs.	342,858			Rs.	564,937
Issue of equity share on exercise of options			137,672				688				70,246				—								(65,835	)
Share based payment expense			—				—				—				—				—				44,074
Profit for the period			—				—				—				—				—				—
Changes in fair value of investments, net of tax expense of Rs.9,122			—				—				—				40,175				—				—
Foreign exchange translation adjustments			—				—				—				—				(416,858	)			—
Minority interest			—				—				—				—				—				—
Balance as of June 30, 2007			168,049,852			Rs.	840,249			Rs.	19,979,083			Rs.	(85,007	)		Rs.	(74,000	)		Rs.	543,176

[Continued on next page]

[Continued from table on page 6, first column(s) repeated]

						Equity shares held
						by a controlled
Particulars		Hedging reserve				trust*				Retained earnings				Minority interest				Total equity
		Amount				Amount				Amount				Amount				Amount
Balance as of April 1, 2008		Rs.	(6,642	)		Rs.	(4,882	)		Rs.	24,211,253				—			Rs.	47,350,814
Issue of equity shares on exercise of options			—				—				—				—				4,399
Share based payment expense			—				—				—				—				34,022
Profit for the period			—				—				1,111,293				—				1,111,293
Changes in fair value of investments, net of tax expense of Rs.2,474			—				—				—				—				2,390
Foreign exchange translation adjustments, net of tax expense of Rs.127,319			—				—				—				—				1,270,668
Effective portion of changes in fair value of cash flow hedges, net of tax benefit of Rs.246,471			(478,657	)			—				—				—				(478,657	)
Balance as of June 30, 2008		Rs.	(485,299	)		Rs.	(4,882	)		Rs.	25,322,546				—			Rs.	49,294,929
Convenience translation into U.S. $		U.S. $	(11,304	)		U.S. $	(114	)		U.S. $	589,857							U.S. $	1,148,263
Balance as of April 1, 2007			—			Rs.	(4,882	)		Rs.	21,101,794			Rs.	10,473			Rs.	42,638,396
Issue of equity share on exercise of options			—				—				—				—				5,099
Share based payment expense			—				—				—				—				44,074
Profit for the period			—				—				1,599,665				—				1,599,665
Changes in fair value of investments, net of tax expense of Rs.9,122			—				—				—				—				40,175
Foreign exchange translation adjustments			—				—				—				—				(416,858	)
Minority interest			—				—				—				(3,023	)			(3,023	)
Balance as of June 30, 2007			—			Rs.	(4,882	)		Rs.	22,701,459			Rs.	7,450			Rs.	43,907,528

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

			For the three months ended June 30,
Particulars		2008				2008				2007
		Convenience
		translation into U.S.$
Cash flows from operating activities:
Profit for the period		U.S.$	25,886			Rs.	1,111,293			Rs.	1,596,642
Adjustments for:
Income tax expense			1,953				83,846				321,715
Profit on sale of investments			(1,742	)			(74,796	)			(15,951	)
Depreciation and amortization			21,730				932,889				739,792
Allowance for doubtful trade receivable			838				35,987				20,306
Inventory write-downs			865				37,120				97,610
(Profit)/loss on sale of property, plant and equipment, net			(66	)			(2,847	)			807
Equity in (gain)/loss of equity accounted investees			(7	)			(297	)			4,028
Unrealized exchange (gain)/loss, net			(6,719	)			(288,446	)			11,133
Interest expense, net			4,043				173,558				156,906
Share based payment expense			792				34,022				44,074
Negative goodwill on acquisition of business			(3,503	)			(150,403	)			—
Changes in operating assets and liabilities:
Trade receivables			(38,527	)			(1,653,958	)			121,525
Inventories			(25,044	)			(1,075,149	)			(1,194,813	)
Other assets			868				37,251				(1,352,952	)
Trade payables			40,808				1,751,906				1,015,114
Other liabilities and provisions			3,719				159,677				1,124,353
Income tax paid			(4,475	)			(192,098	)			(415,554	)
Net cash from operating activities		U.S.$	21,420			Rs.	919,555			Rs.	2,274,735
Cash flows used in investing activities:
Expenditures on property, plant and equipment			(30,286	)			(1,300,174	)			(975,791	)
Proceeds from sale of property, plant and equipment			179				7,697				3,768
Purchase of investments			(136,665	)			(5,867,019	)			(198,054	)
Proceeds from sale of investments			173,187				7,434,925				210,591
Expenditures on intangible assets			(2,362	)			(101,420	)			—
Payment of contingent consideration			(605	)			(25,964	)			(48,671	)
Cash paid for acquisition of business			(71,956	)			(3,089,062	)			—
Interest received			1,295				55,610				263,591
Net cash used in investing activities		U.S.$	(67,212	)		Rs.	(2,885,407	)		Rs.	(744,566	)
Cash flows used in financing activities:
Interest paid			(5,536	)			(237,655	)			(363,254	)
Proceeds from issuance of equity shares			102				4,399				5,099
Repayment of short term loans and borrowings, net			(39,071	)			(1,677,334	)			(1,651,318	)
Repayment of long term loans and borrowings, net			(11,134	)			(477,984	)			(6,248,407	)
Net cash used in financing activities		U.S.$	(55,639	)		Rs.	(2,388,574	)		Rs.	(8,257,880	)
Net decrease in cash and cash equivalents			(101,431	)			(4,354,426	)			(6,727,711	)
Effect of exchange rate changes on cash and cash equivalents			4,567				196,040				(221,443	)
Cash and cash equivalents at the beginning of the period			162,742				6,986,513				18,061,576
Cash and cash equivalents at the end of the period		U.S.$	65,878			Rs.	2,828,127			Rs.	11,112,422

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

1.		Reporting Entity
		Dr. Reddy’s Laboratories Limited (“DRL” or the “parent company”), together with its subsidiaries (collectively, the “Company”), is a leading India-based pharmaceutical company headquartered in Hyderabad, India. The Company’s principal areas of operation are in pharmaceutical services and active ingredients, global generics, and proprietary products. The Company’s principal research and development facilities are located in Andhra Pradesh, India and in the United States; its principal manufacturing facilities are located in Andhra Pradesh, India, Himachal Pradesh, India and Cuernavaca-Cuautla, Mexico; and its principal marketing facilities are located in India, Russia, the United States, the United Kingdom, Brazil and Germany. The Company’s shares trade on the Bombay Stock Exchange and the National Stock Exchange in India and, since April 11, 2001, also on the New York Stock Exchange in the United States. These unaudited condensed consolidated interim financial statements were authorized for issuance by the Company’s Board of Directors on March 4, 2009.
2.		Basis of preparation of financial statements
a.		Statement of compliance
		These condensed consolidated interim financial statements as at and for the three months ended June 30, 2008 have been prepared in accordance with IFRS and its interpretations issued by IASB. These are the Company’s first IFRS condensed consolidated interim financial statements forming part of the period covered by the first IFRS annual financial statements for the year ending March 31, 2009 and IFRS 1, “First-time adoption of International Financial Reporting Standards,” has been applied. These condensed consolidated interim financial statements do not include all the information required for full annual consolidated financial statements and are prepared in accordance with IAS 34, “Interim Financial Reporting”.
		An explanation of how the transition to IFRS has affected the reported financial position and financial performance of the Company is provided in Note 4. This Note includes reconciliations of equity and profit or loss for comparative periods under U.S. GAAP (sometimes referred to herein as “Previous GAAP”) to those reported for those periods under IFRS.
b.		Basis of preparation
		These condensed consolidated interim financial statements have been prepared on the basis of relevant IFRS that are effective or available for early adoption at the Company’s first IFRS annual reporting date, March 31, 2009. Based on these IFRS, the Board of Directors has made assumptions about the accounting policies expected to be adopted (“accounting policies”) when the first IFRS annual financial statements are prepared for the year-ending March 31, 2009.
		The IFRS that will be effective or available for voluntary early adoption in the annual financial statements for the period ending March 31, 2009 are still subject to change and to the issue of additional interpretation(s) and therefore cannot be determined with certainty. Accordingly, the accounting policies for such annual period that are relevant to this interim financial information will be determined only when the first IFRS financial statements are prepared at March 31, 2009.
		The preparation of the condensed consolidated interim financial statements in accordance with IAS 34 resulted in changes to the accounting policies as compared with the most recent annual financial statements prepared under Previous GAAP. The accounting policies set out below have been applied consistently to all periods presented in these condensed consolidated interim financial statements. They also have been applied in preparing an opening IFRS balance sheet at April 1, 2007 for the purposes of the transition to IFRS, as required by IFRS 1. The impact of the transition from Previous GAAP to IFRS is explained in Note 4.
c.		Basis of measurement/accounting convention
		These condensed consolidated interim financial statements have been prepared on the historical cost basis and on an accrual basis, except for the following:

	•		derivative financial instruments are measured at fair value; and
	•		available-for-sale financial assets are measured at fair value.

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

2.		Basis of preparation of financial statements (continued)
d.		Functional and presentation currency
		The condensed consolidated interim financial statements are presented in Indian rupees, which is the functional currency of DRL. Functional currency of an entity is the currency of the primary economic environment in which the entity operates.
		In respect of all non-Indian subsidiaries that operate as marketing arms of the parent company in their respective countries/regions, the functional currency has been determined to be the functional currency of the parent company (i.e., the Indian rupee). Accordingly, the operations of these entities are largely restricted to import of finished goods from the parent company in India, sale of these products in the foreign country and remittance of the sale proceeds to the parent company. The cash flows realized from sale of goods are readily available for remittance to the parent company and cash is remitted to the parent company on a regular basis. The costs incurred by these entities are primarily the cost of goods imported from the parent company. The financing of these subsidiaries is done directly or indirectly by the parent company.
		In respect of subsidiaries whose operations are self contained and integrated within their respective countries/regions, the functional currency has been determined to be the local currency of those countries/regions. The assets and liabilities of such subsidiaries are translated into Indian rupees at the rate of exchange prevailing as at the reporting date. Revenues and expenses are translated into Indian rupees at average exchange rates prevailing during the year. Resulting translation adjustments are included in foreign currency translation reserve.
		All financial information presented in Indian Rupees has been rounded to the nearest thousand.
e.		Convenience translation
		The accompanying unaudited condensed consolidated interim financial statements have been prepared in Indian rupees. Solely for the convenience of the reader, the unaudited condensed consolidated interim financial statements as of June 30, 2008 have been translated into United States dollars at the noon buying rate in New York City on June 30, 2008 for cable transfers in Indian rupees, as certified for customs purposes by the Federal Reserve Bank of New York of U.S.$1.00 = Rs.42.93. No representation is made that the Indian rupee amounts have been, could have been or could be converted into U.S. dollars at such a rate or any other rate.
f.		Use of estimates and judgments
		The preparation of condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.
		Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following Notes:

	•		Note 3(b) — Assessment of functional currency for foreign operations
	•		Note 3(c) and 7 — Financial instruments
	•		Note 3(h) — Measurement of recoverable amounts of cash-generating units
	•		Note 3(j) — Provisions
	•		Note 3(k) — Sales returns, rebates and charge back provisions
	•		Note 3(m) — Determination of annual effective tax rate in interim periods and recoverability of deferred tax assets
	•		Note 6 — Business combinations
	•		Note 21 — Contingencies

3.		Significant accounting policies
a.		Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. In assessing control, potential voting rights that currently are exercisable are taken into account. The financial statements of subsidiaries are included in the condensed consolidated interim financial statements from the date that control commences until the

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

3.		Significant accounting policies (continued)
a.		Basis of consolidation (continued)

date that control ceases. The accounting policies of subsidiaries have been changed when necessary to align them with the policies adopted by the Company.

Special purpose entities

The Company has established certain special purpose entities (“SPEs”) for business purposes. The Company does not have any direct or indirect shareholdings in these entities. A SPE is consolidated if, based on an evaluation of the substance of its relationship with the Company and the SPE’s risks and rewards, the Company concludes that it controls the SPE. SPEs controlled by the Company were established under terms that impose strict limitations on the decision-making powers of the SPE’s management and that result in the Company receiving the majority of the benefits related to the SPE’s operations and net assets, being exposed to risks incident to the SPE’s activities, and retaining the majority of the residual or ownership risks related to the SPE or its assets.

Associates and jointly controlled entities (equity accounted investees)

Associates are those entities in which the Company has significant influence, but not control, over the financial and operating policies. Significant influence is presumed to exist when the Company holds between 20 and 50 percent of the voting power of another entity. Joint ventures are those entities over whose activities the Company has joint control, established by contractual agreement and requiring unanimous consent for strategic financial and operating decisions. Associates and jointly controlled entities are accounted for using the equity method (equity accounted investees) and are initially recognized at cost. The condensed consolidated interim financial statements include the Company’s share of the income and expenses and equity movements of equity accounted investees, after adjustments to align the accounting policies with those of the Company, from the date that significant influence or joint control commences until the date that significant influence or joint control ceases. When the Company’s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest (including any long term investments) is reduced to zero and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee.

The Company does not consolidate entities where the minority shareholders have certain significant participating rights that provide for effective involvement in significant decisions in the ordinary course of business of such entities. Investments in such entities are accounted by the equity method of accounting.

Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the condensed consolidated interim financial statements. Unrealized gains arising from transactions with equity accounted investees are eliminated against the investment to the extent of the Company’s interest in the investee. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment.

b.

Foreign currency

Transactions in foreign currencies are translated to the respective functional currencies of group entities at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at the end of the period. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date that the fair value was determined. Foreign currency differences arising upon retranslation are recognized in profit or loss, except for differences arising upon qualifying cash flow hedges, which are recognized directly in equity.

The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising upon acquisition, are translated to reporting currency at exchange rates at the reporting date. The income and expenses of

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

3.		Significant accounting policies (continued)
b.		Foreign currency (continued)

foreign operations are translated to reporting currency at average rates prevailing during the year.

Foreign currency differences are recognized directly in equity. Such differences have been recognized in the foreign currency translation reserve (“FCTR”). When a foreign operation is disposed of, in part or in full, the relevant amount in the FCTR is transferred to profit or loss.

Foreign exchange gains and losses arising from a monetary item receivable from or payable to a foreign operation, the settlement of which is neither planned nor likely in the foreseeable future, are considered to form part of a net investment in a foreign operation and are recognized directly in equity in the FCTR.

c.

Financial instruments

Non-derivative financial instruments

Non-derivative financial instruments is comprised of investments in equity and debt securities, trade receivables, certain other assets, cash and cash equivalents, loans and borrowings, and trade payables and certain other liabilities.

Non-derivative financial instruments are recognized initially at fair value plus, for instruments not at fair value through profit or loss, any directly attributable transaction costs. Subsequent to initial recognition non-derivative financial instruments are measured as described below.

Cash and cash equivalents

Cash and cash equivalents is comprised of cash balances, current and time deposits with banks. Bank overdrafts that are repayable on demand and form an integral part of the Company’s cash management are included as a component of cash and cash equivalents for the purpose of the statement of cash flows.

Held-to-maturity investments

If the Company has the positive intent and ability to hold debt securities to maturity, then they are classified as held-to-maturity. Held-to-maturity investments are measured at amortized cost using the effective interest method, less any impairment losses.

Available-for-sale financial assets

The Company’s investments in equity securities and certain debt securities are classified as available-for-sale financial assets. Subsequent to initial recognition, they are measured at fair value and changes therein, other than impairment losses and foreign exchange gains and losses on available-for-sale monetary items, are recognized directly in equity. When an investment is derecognized, the cumulative gain or loss in equity is transferred to profit or loss.

Financial assets at fair value through profit or loss

An instrument is classified at fair value through profit or loss if it is held for trading or is designated as such upon initial recognition. Financial instruments are designated at fair value through profit or loss if the Company manages such investments and makes purchase and sale decisions based on their fair value in accordance with the Company’s documented risk management or investment strategy. Upon initial recognition, attributable transaction costs are recognized in profit or loss when incurred. Financial instruments at fair value through profit or loss are measured at fair value, and changes therein are recognized in profit or loss.

Other

Other non-derivative financial instruments are measured at amortized cost using the effective interest method, less any impairment losses.

Derivative financial instruments

The Company holds derivative financial instruments to hedge its foreign currency exposure. Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss when incurred. Subsequent to

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

3.		Significant accounting policies (continued)
c.		Financial instruments (continued)

initial recognition, derivatives are measured at fair value, and changes therein are accounted for as described below.

Cash flow hedges

Changes in the fair value of the derivative hedging instrument designated as a cash flow hedge are recognized directly in equity to the extent that the hedge is effective. To the extent that the hedge is ineffective, changes in fair value are recognized in profit or loss. If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated or exercised, then hedge accounting is discontinued prospectively. The cumulative gain or loss previously recognized in equity remains there until the forecast transaction occurs. When the hedged item is a non-financial asset, the amount recognized in equity is transferred to the carrying amount of the asset when it is recognized. In other cases the amount recognized in equity is transferred to profit or loss in the same period that the hedged item affects profit or loss.

Economic hedges

Hedge accounting is not applied to derivative instruments that economically hedge monetary assets and liabilities denominated in foreign currencies. Changes in the fair value of such derivatives are recognized in profit or loss as part of foreign currency gains and losses.

Share capital

Ordinary shares

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized as a deduction from equity, net of any tax effects.

d.

Property, plant and equipment

Recognition and measurement

Items of property, plant and equipment including assets acquired under a finance lease are measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and direct labor, any other costs directly attributable to bringing the asset to a working condition for its intended use, and the costs of dismantling and removing the items and restoring the site on which they are located. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment. Borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized as part of the cost of that asset.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Gains and losses upon disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized net within “other income/expense, net” in profit or loss.

Subsequent costs

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of property, plant and equipment are recognized in profit or loss as incurred.

Depreciation

Depreciation is recognized in profit or loss on a straight-line basis over the estimated useful lives of each part of an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives, unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Land is not depreciated.

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

3.		Significant accounting policies (continued)
d.		Property, plant and equipment (continued)

The estimated useful lives for the current and comparative periods are as follows:

Buildings
- Factory and administrative buildings		25 - 50 years
- Ancillary structures		3 - 15 years
Plant and equipment		3 - 15 years
Furniture, fixtures and office equipment		4 - 10 years
Vehicles		4 - 5 years
Computer equipment		3 - 5 years

Depreciation methods, useful lives and residual values are reviewed at each reporting date.

e.

Intangible assets

Goodwill

Goodwill (negative goodwill) arises upon the acquisition of subsidiaries, associates and joint ventures.

Acquisitions prior to April 1, 2007

As part of its transition to IFRS, the Company elected to restate only those business combinations that occurred on or after April 1, 2007. In respect of acquisitions prior to April 1, 2007, goodwill represents the amount recognized under Previous GAAP.

Acquisitions on or after April 1, 2007

For acquisitions on or after April 1, 2007, goodwill represents the excess of the cost of the acquisition over the Company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the acquiree. When the excess is negative (“negative goodwill”), it is recognized immediately in profit or loss.

Acquisitions of minority interests

Goodwill arising upon the acquisition of a minority interest in a subsidiary represents the excess of the cost of the additional investment over the carrying amount of the net assets acquired at the date of exchange.

Subsequent measurement

Goodwill is measured at cost less accumulated impairment losses. In respect of equity accounted investees, the carrying amount of goodwill is included in the carrying amount of the investment.

Research and development

Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss when incurred.

Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. The expenditures capitalized include the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use. Borrowing costs related to the development of qualifying assets are capitalized as a part of the cost of that asset. Other development expenditures are recognized in profit or loss as incurred.

Internal product development expenditures are capitalized only if they meet the recognition criteria as mentioned above. Where regulatory and other uncertainties are such that the criteria are not met, the expenditures are recognized in the Company’s income statement. This is almost invariably the case prior to approval of the drug by the relevant

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

3.		Significant accounting policies (continued)
e.		Intangible assets (continued)

regulatory authority. Where, however, the recognition criteria are met, intangible assets are capitalized and amortized on a straight-line basis over their useful economic lives from product launch. Payments to in-license products and compounds from external third parties for new research and development projects (in-process research and development), generally taking the form of up-front payments and milestones, are capitalized and amortized, generally on a straight-line basis, over their useful economic lives from product launch.

Intangible assets relating to products in development (both internally generated and externally acquired), other intangible assets not available for use and intangible assets having indefinite useful life are subject to impairment testing at each balance sheet date. All other intangible assets are tested for impairment when there are indications that the carrying value may not be recoverable. Any impairment losses are recognized immediately in the income statement. Trademarks with indefinite useful lives are tested for impairment annually.

Capitalized development expenditures are measured at cost less accumulated amortization and accumulated impairment losses.

Advances paid for research and development activities are shown as other receivables in the balance sheet until the time that actual cost is incurred for such research and development activities. Such amounts are capitalized or recognized as an expense, as the case may be, as the related goods are delivered or the related services are performed.

Other intangible assets

Other intangible assets that are acquired by the Company, which have finite useful lives, are measured at cost less accumulated amortization and accumulated impairment losses.

Subsequent expenditures

Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures, including expenditures on internally generated goodwill and brands, are recognized in profit or loss as incurred.

Amortization

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets, other than for goodwill, intangible assets not available for use and intangible assets having indefinite life, from the date that they are available for use. The estimated useful lives for the current and comparative periods are as follows:

Trademarks with finite useful life		3 - 10 years
Product related intangibles		6 - 15 years
Beneficial toll manufacturing contract		24 months
Non-competition arrangements		1.5 - 10 years
Marketing rights		3 - 16 years
Customer-related intangibles		2 - 11 years
Other intangibles		5 - 15 years

f.

Leases

At the inception of a lease, the lease arrangement is classified as either a finance lease or an operating lease, based on the substance of the lease arrangement.

Finance leases

A finance lease is recognized as an asset and a liability at the commencement of the lease, at the lower of the fair value of the asset and the present value of the minimum lease payments. Initial direct costs, if any, are also capitalized and,

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

3.		Significant accounting policies (continued)
f.		Leases (continued)

subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to that asset. Minimum lease payments made under finance leases are apportioned between the finance expense and the reduction of the outstanding liability. The finance expense is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Operating leases

Other leases are operating leases and the leased assets are not recognized on the Company’s balance sheet. Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease.

g.

Inventories

Inventories consist of raw materials, stores and spares, work in progress and finished goods and are measured at the lower of cost and net realizable value. The cost of all categories of inventories, except stores and spares, is based on the first-in first-out principle. Stores and spares is comprised of packing materials, engineering spares (such as machinery spare parts) and consumables (such as lubricants, cotton waste and oils), which are used in operating machines or consumed as indirect materials in the manufacturing process, where cost is based on a weighted average method. Cost includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of finished goods and work in progress, cost includes an appropriate share of overheads based on normal operating capacity. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

h.

Impairment

Financial assets

A financial asset is assessed at each reporting date to determine whether there is any objective evidence that it is impaired. A financial asset is considered to be impaired if objective evidence indicates that one or more events have had a negative effect on the estimated future cash flows of that asset.

An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount, and the present value of the estimated future cash flows discounted at the original effective interest rate. An impairment loss in respect of an available-for-sale financial asset is calculated by reference to its fair value.

Individually significant financial assets are tested for impairment on an individual basis. The remaining financial assets are assessed collectively in groups that share similar credit risk characteristics.

All impairment losses are recognized in profit or loss. Any cumulative loss in respect of an available-for-sale financial asset recognized previously in equity is transferred to profit or loss. An impairment loss is reversed if the reversal can be related objectively to an event occurring after the impairment loss was recognized. For financial assets measured at amortized cost and available-for-sale financial assets that are debt securities, the reversal is recognized in profit or loss. For available-for-sale financial assets that are equity securities, the reversal is recognized directly in equity.

Non-financial assets

The carrying amounts of the Company’s non-financial assets, other than inventories and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. For goodwill and intangible assets that have indefinite lives or that are not yet available for use, the recoverable amount is estimated each year at the same time.

The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

3.		Significant accounting policies (continued)
h.		Impairment (continued)

asset. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the “cash-generating unit”). The goodwill acquired in a business combination, for the purpose of impairment testing, is allocated to cash-generating units that are expected to benefit from the synergies of the combination.

An impairment loss is recognized if the carrying amount of an asset or its cash-generating unit exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss. Impairment losses recognized in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit (group of units) on a pro rata basis.

An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

i.

Employee benefits

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to recognized provident funds and approved superannuation schemes which are defined contribution plans are recognized as an employee benefit expense in profit or loss when they are due.

Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in future payments is available.

Defined benefit plans

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The Company’s net obligation in respect of an approved gratuity plan, which is a defined benefit plan, and certain other defined benefit plans is calculated separately for each plan by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods; that benefit is discounted to determine its present value. Any unrecognized past service costs and the fair value of any plan assets are deducted. The discount rate is the yield at the reporting date on risk free government bonds that have maturity dates approximating the terms of the Company’s obligations and that are denominated in the same currency in which the benefits are expected to be paid. The calculation is performed annually by a qualified actuary using the projected unit credit method. When the calculation results in a benefit to the Company, the recognized asset is limited to the net total of any unrecognized past service costs and the present value of any future refunds from the plan or reductions in future contributions to the plan.

When the benefits of a plan are improved, the portion of the increased benefit relating to past service by employees is recognized in profit or loss on a straight-line basis over the average period until the benefits become vested. To the extent that the benefits vest immediately, the expense is recognized immediately in profit or loss.

The Company recognizes actuarial gains and losses using the corridor method. Under this method, to the extent that any cumulative unrecognized actuarial gain or loss exceeds 10% of the greater of the present value of the defined benefit obligation and the fair value of plan assets, that portion is recognized in income over the expected average remaining working lives of the employees participating in the plan. Otherwise, the actuarial gain or loss is not recognized.

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

3.		Significant accounting policies (continued)
i.		Employee benefits (continued)

Termination benefits

Termination benefits are recognized as an expense when the Company is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense if the Company has made an offer encouraging voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably.

Short-term benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.

A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Compensated leave of absence

Eligible employees are entitled to accumulate compensated absences up to prescribed limits in accordance with the Company’s policy and receive cash in lieu thereof. The Company measures the expected cost of accumulating compensated absences as the additional amount that the Company entities expect to pay as a result of the unused entitlement that has accumulated at the balance sheet date. Such measurement is based on actuarial valuation as at the balance sheet date carried out by a qualified actuary.

Share-based payment transactions

The grant date fair value of options granted to employees, calculated using the Black-Scholes model, is recognized as an employee expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the options. The increase in equity recognized in connection with a share based payment transaction is presented as a separate component in equity. The amount recognized as an expense is adjusted to reflect the actual number of share options that vest.

j.

Provisions

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

Restructuring

A provision for restructuring is recognized when the Company has approved a detailed and formal restructuring plan, and the restructuring either has commenced or has been announced publicly. Future operating costs are not provided for.

Onerous contracts

A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Company recognizes any impairment loss on the assets associated with that contract.

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

3.		Significant accounting policies (continued)
k.		Revenue

Sale of goods

Revenue is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods and the amount of revenue can be measured reliably. Revenue from the sale of goods includes excise duty and is measured at the fair value of the consideration received or receivable, net of returns, sales tax and applicable trade discounts and allowances.

Revenue from domestic sales of generic products is recognized upon delivery of products to stockists by clearing and forwarding agents of the Company. Revenue from domestic sales of active pharmaceutical ingredients and intermediates is recognized on delivery of products to customers, from the factories of the Company. Revenue from export sales is recognized when the significant risks and rewards of ownership of products are transferred to the customers, which is based upon the terms of the applicable contract.

Sales of generics in India are made through clearing and forwarding agents to stockists. Significant risks and rewards in respect of ownership of generic products are transferred by the Company when the goods are delivered to stockists from clearing and forwarding agents. Clearing and forwarding agents are generally compensated on a commission basis as a percentage of sales made by them.

Sales of active pharmaceutical ingredients and intermediates in India are made directly to the end customers generally, formulation manufacturers, from the factories of the Company. Significant risks and rewards in respect of ownership of active pharmaceuticals ingredients are transferred by the company on delivery of the products to the customers. Sales of active pharmaceutical ingredients and intermediates outside India are made directly to the end customers, generally stockists or formulations manufacturers, from the parent company or its consolidated subsidiaries.

The Company has entered into marketing arrangements with certain marketing partners for sale of goods in certain overseas territories. Under such arrangements, the Company sells generic products to the marketing partners at a price agreed in the arrangement. Revenue is recognized on these transactions upon delivery of products to the marketing partners. An additional amount, representing profit share, is recognized as revenue, on the basis of ultimate net sale proceeds, only when realization is certain.

Provisions for chargeback, rebates, discounts and medicaid payments are estimated and provided for in the year of sales and recorded as reduction of revenue. A chargeback claim is a claim made by the wholesaler for the difference between the price at which the product is initially invoiced to the wholesaler and the net price at which it is agreed to be procured from the Company. Provision for such chargebacks are accrued and estimated based on historical average chargeback rate actually claimed over a period of time, current contract prices with wholesalers/other customers and average inventory holding by the wholesaler. Such provisions are disclosed as a reduction of trade receivable.

The Company accounts for sales returns by recording an accrual based on the Company’s estimate of expected sales returns. The Company deals in various products and operates in various markets. Accordingly, the Company’s estimate of sales returns is determined primarily by its experience in these markets. In respect of established products, the Company determines an estimate of sales returns accrual primarily based on historical experience of such sales returns. Additionally, other factors that the Company considers in determining the estimate include levels of inventory in the distribution channel, estimated shelf life, product discontinuances, price changes of competitive products, and introduction of competitive new products, to the extent each of these factors impact the Company’s

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

3.		Significant accounting policies (continued)
k.		Revenue (continued)

business and markets. The Company considers all these factors and adjusts the sales return accrual to reflect its actual experience. With respect to new products introduced by the Company, those are either extensions of an existing line of product or in a general therapeutic category where the Company has historical experience. The Company’s new product launches have historically been in therapeutic categories where established products exist and are sold either by the Company or its competitors. The Company has not yet introduced products in a new therapeutic category where the sales returns experience of such products is not known. The amount of sales returns for the Company’s newly launched products do not significantly differ from sales returns experience of current products marketed by the Company or its competitors (as the Company understands based on industry publications). Accordingly, the Company does not expect sales returns for new products to be significantly different from expected sales returns of current products. The Company evaluates sales returns of all its products at the end of each reporting period and records necessary adjustments, if any.

Services

Revenue from services rendered, which primarily relate to contract research, is recognized in profit or loss in proportion to the stage of completion of the transaction at the reporting date. The stage of completion is assessed by reference to cost incurred as a percentage of total expected cost.

License fees

Non-refundable milestone payments are recognized in the consolidated statement of operations as and when related services are rendered or agreed milestones are achieved in accordance with the terms of the license agreement, and when the Company has no future obligations or continuing involvement pursuant to such milestone payments. Non-refundable up-front license fees are deferred and recognized when the milestones are earned, in proportion to the amount of each milestone earned bears to the total milestone payments agreed in the license agreement. Where the upfront license fees are a composite amount and cannot be attributed to a specific molecule, they are amortized over the development period. The milestone payments increase during the development period as the risk involved decreases. The agreed milestone payments reflect the progress of the development of the molecule and may not be spread evenly over the development period. Accordingly, the milestone payments are a fair representation of the extent of progress made in the development of these underlying molecules. In the event the development of a molecule is discontinued, the corresponding amount of deferred revenue is recognized in the consolidated statement of operations in the period in which the project is terminated.

The Company has entered into certain dossier sales, licensing arrangements and supply arrangements that include certain performance obligations. Based on an evaluation of whether or not these obligations are inconsequential or perfunctory, the Company defers the upfront payments received under these arrangements. Such deferred revenue is recognized in the consolidated statement of operations in the period in which the Company completes remaining performance obligations.

Export entitlements

Export entitlements are recognized as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

l.

Finance income and expenses

Finance income is comprised of interest income on funds invested (including available-for-sale financial assets), dividend income, gains on the disposal of available-for-sale financial assets, changes in the fair value of financial assets at fair value through profit or loss, and gains on hedging instruments that are recognized in profit or loss. Interest income is recognized as it accrues in profit or loss, using the effective interest method. Dividend income is recognized in profit or loss on the date that the Company’s right to receive payment is established.

Finance expenses is comprised of interest expense on loans and borrowings, unwinding of the discount on provisions, changes in the fair value of financial assets at fair value through profit or loss, impairment losses recognized on

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

3.		Significant accounting policies (continued)
l.		Finance income and expenses (continued)

financial assets, and losses on hedging instruments that are recognized in profit or loss. All borrowing costs are recognized in profit or loss using the effective interest method.

Foreign currency gains and losses are reported on a net basis.

m.

Income tax

Income tax expense is comprised of current and deferred tax. Income tax expense is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity.

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognized using the balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit, and differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising upon the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.

A deferred tax asset is recognized to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Additional income taxes that arise from the distribution of dividends are recognized at the same time as the liability to pay the related dividend is recognized.

n.

Earnings per share

The Company presents basic and diluted earnings per share (“EPS”) data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares, which is comprised of share options granted to employees.

o.

New standards and interpretations not yet adopted

A number of new standards, and interpretations and amendments to standards and interpretations, are not yet effective for the year ending March 31, 2009, and have not been applied in preparing these condensed consolidated interim financial statements:

	•		Revised IAS 1, “Presentation of Financial Statements” (2007) becomes mandatory for the Company’s consolidated financial statements for the year ending March 31, 2010 and is not expected to have any material impact on the presentation of the consolidated financial statements.
	•		Revised IFRS 3, “Business Combinations” (2008) becomes mandatory for the Company’s consolidated financial statements for the year ending March 31, 2011, and will be applied prospectively.

3.		Significant accounting policies (continued)
o.		New standards and interpretations not yet adopted (continued)

	•		Amended IAS 27, “Consolidated and Separate Financial Statements” (2008) becomes mandatory for the Company’s consolidated financial statements for the year ending March 31, 2011, and will be applied prospectively.
	•		Amendment to IFRS 2, “Share-based Payment — Vesting Conditions and Cancellations” becomes mandatory for the Company’s consolidated financial statements for the year ending March 31, 2010, with retrospective application. The Company is currently in the process of evaluating the potential impact of the revised standard on its consolidated financial statements.
	•		Amendments to IAS 32, “Financial Instruments: Presentation and IAS 1 Presentation of Financial Statements — Puttable Financial Instruments and Obligations Arising on Liquidation” becomes mandatory for the Company’s consolidated financial statements for the year ending March 31, 2010 and retrospective application is permitted. The adoption of this standard is not expected to have any material impact on the consolidated financial statements.
	•		Revised IAS 23, “Borrowing Costs” becomes mandatory for the Company’s consolidated financial statements for the year ending March 31, 2010. As the Company currently follows a policy of capitalizing borrowing costs, this new standard will have no impact on the Company’s consolidated financial statements.
	•		IFRIC 13, “Customer Loyalty Programmes” becomes mandatory for the Company’s consolidated financial statements for the year ending March 31, 2010 and is not expected to have any impact on the consolidated financial statements.
	•		IFRIC 14, “IAS 19 — The Limit on a Defined Benefit Asset, Minimum Funding Requirements and their Interaction” becomes mandatory for the Company’s consolidated financial statements for the year ending March 31, 2010 and is not expected to have any material impact on its consolidated financial statements.

p.

Standards early adopted

•

IFRS 8, “Operating Segments,” introduces the “management approach” to segment reporting. IFRS 8 is mandatory for the Company’s consolidated financial statements for the year ending March 31, 2010. IFRS 8 requires presentation and disclosure of segment information based on the internal reports regularly reviewed by the Company’s Chief Operating Decision Maker in order to assess each segment’s performance and to allocate resources to them. The Company has early adopted IFRS 8 and presented segment information in respect of its operating segments in its unaudited condensed consolidated interim financial statements following the management approach, based on the internal reports regularly reviewed by the Company’s Chief Operating Decision Maker.

4.

Explanation of transition to IFRS

As stated in Note 2(a), these are the Company’s first condensed consolidated interim financial statements which are part of the period covered by the first annual consolidated financial statements prepared in accordance with IFRS.

In preparing these condensed consolidated interim financial statements, the Company has availed itself of certain exemptions and exceptions in accordance with IFRS 1.

a.

Exemptions from retrospective application

Following are the exemptions which the Company has opted to apply or not to apply:

i.

Business combinations exemption: The Company has applied the exemption as provided in IFRS 1 on non-application of IFRS 3, “Business Combinations” to business combinations consummated prior to April 1, 2007 (the “Transition Date”), pursuant to which goodwill arising from business combination has been stated at the carrying amount prior to the date of transition under Previous GAAP. The Company has also applied the

4.

Explanation of transition to IFRS (continued)

a.

Exemptions from retrospective application (continued)

			exemption for past business combinations to acquisitions of investments in associates consummated prior to the Transition Date.
	ii.		Fair value as deemed cost exemption: The Company has not elected to measure any item of property, plant and equipment at its fair value at the Transition Date; property, plant and equipment have been measured at cost in accordance with IFRS.
	iii.		Employee benefits exemption: The Company has elected to apply the exemption as provided in IFRS 1 and recognized cumulative actuarial gains and losses as of the Transition Date as an adjustment to the opening retained earnings. The Company will continue to apply the corridor approach in subsequent periods.
	iv.		Cumulative translation differences exemption: The Company had accumulated the translation differences in a separate component of equity under Previous GAAP. Upon transition to IFRS, the treatment of recording translation differences in equity did not undergo any change and consequently the optional exemption of setting cumulative differences as zero and reclassifying the amount recognized in accordance with Previous GAAP as retained earnings as at the Transition Date was not required to be applied.
	v.		Compound financial instruments: The Company did not have any compound financial instrument as of the Transition Date. Consequently, upon adoption of IFRS the optional exemption allowed of non-segregation of the liability component if such component was no longer outstanding on the Transition Date is not applicable to the Company.
	vi.		Assets and liabilities of subsidiaries, associates and joint ventures exemption: All entities of the Company are transitioning to IFRS on the same date. Consequently, this exemption is not applicable to the Company.
	vii.		Share-based payment transaction exemption: Under Previous GAAP, the Company had applied the fair value recognition and measurement principles similar to those prescribed under IFRS 2 for all options granted before the Transition Date. Consequently, upon transition to IFRS, the optional exemption is not applicable to the Company.
	viii.		Fair value measurement of financial assets or liabilities at initial recognition: The Company has not applied the amendment offered by the revision of IAS 39, “Financial Instruments: Recognition and Measurement”, upon the initial recognition of the financial instruments measured at fair value through the income statement where there is no active market.
	ix.		Designation of financial assets and financial liabilities exemption: The Company did not have any financial assets or liabilities as of the Transition Date which were required to be designated and which met the required criteria given in IFRS 1 as a financial asset or financial liability at fair value through profit or loss.
	x.		Changes in decommissioning liabilities included in the cost of property, plant and equipment exemption: The Company does not have any material decommissioning liabilities in the cost of property, plant and equipment. Consequently, this exception is not applicable to the Company.
	xi.		Leases exemption: The Company has no arrangements containing a lease as defined under IFRIC 4, “Determining whether an arrangement contains a lease”. Consequently, this exemption is not applicable to the Company.
	xii.		Financial asset or an intangible asset accounted for in accordance with IFRIC 12, Service Concession Arrangements exemption: The Company has no arrangements which would be classified under Service Concession Arrangements. Consequently, this exemption is not applicable to the Company.
	xiii.		Insurance contracts: The Company does not issue any insurance contracts. Consequently, this exemption is not applicable to the Company.

4.

Explanation of transition to IFRS (continued)

b.

Exceptions from full retrospective application

	i.		Derecognition of financial assets and liabilities exception: Financial assets and liabilities derecognized before January 1, 2004 are not re-recognized under IFRS. No arrangements were identified that had to be assessed under this exception.
	ii.		Hedge accounting exception: The Company has not identified any hedging relationships existing as of the Transition Date. Consequently, this exception of not reflecting in its opening IFRS statement of financial position a hedging relationship of a type that does not qualify for hedge accounting under IAS 39 is not applicable to the Company.
	iii.		Estimates exception: Upon an assessment of the estimates made under Previous GAAP, the Company has concluded that there was no necessity to revise such estimates under IFRS except as a part of transition where estimates were required by IFRS and not required by Previous GAAP or where estimates made under Previous GAAP were to be revised to comply with IFRS, but such estimates reflected the conditions as at the Transition Date.
	iv.		Assets classified as held for sale and discontinued operations: The Company has not classified any asset as held for sale and therefore this exception is not applicable.

c.

Reconciliations

The accounting policies as stated above have been applied in preparing the condensed consolidated interim financial statements for the three months ended June 30, 2008, the comparative information for the three months ended June 30, 2007, the consolidated financial statements for the year ended March 31, 2008 and the preparation of an opening IFRS balance sheet at April 1, 2007. In preparing its opening IFRS balance sheet, comparative information for the three months ended June 30, 2007 and financial statements for the year ended March 31, 2008, the Company has adjusted amounts reported previously in financial statements prepared in accordance with Previous GAAP.

An explanation of how the transition from Previous GAAP to IFRS has affected the Company’s financial position, financial performance and cash flows is set out in the following tables and the Notes that accompany the tables.

						As at
		Notes				April 1, 2007				June 30, 2007				March 31, 2008
Total equity under Previous GAAP						Rs.	41,578,228			Rs.	43,095,139			Rs.	47,066,584
Impairment impact on intangibles			A				621,311				621,311				99,315
Amortization reversal on intangibles impaired			A				—				4,070				26,472
Employee benefits			B				(25,573	)			(67,985	)			16,413
Fringe benefit tax on employee stock options			D				—				(61,147	)			(52,946	)
Tax adjustments			E				453,957				313,711				169,508
Foreign exchange rate impact on above adjustments							—				(5,021	)			25,468
Equity under IFRS before reclassification of minority interest							42,627,923				43,900,078				47,350,814
Minority interest			F				10,473				7,450				—
Total equity under IFRS						Rs.	42,638,396			Rs.	43,907,528			Rs.	47,350,814

						For three months ended				For the Year ended
		Notes				June 30, 2007				March 31, 2008
Profit under Previous GAAP						Rs.	1,825,068			Rs.	4,678,042
Impairment impact on intangibles			A				—				(521,996	)
Amortization reversed on intangibles impaired			A				4,070				26,472
Employee benefits			B				(42,412	)			(18,693	)
Cash flow hedge related adjustments			C				—				(25,490	)
Fringe benefit tax on employee stock options			D				(61,147	)			(52,946	)
Tax adjustments			E				(140,246	)			(257,015	)
Minority Interest			F				(3,023	)			(10,473	)
Foreign exchange rate impact on above adjustments							14,332				18,372
Profit under IFRS						Rs.	1,596,642			Rs.	3,836,273

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

4.

Explanation of transition to IFRS (continued)

c.

Reconciliations (continued)

iii. Notes to reconciliation

A. Impairment

Under Previous GAAP, impairment testing for an amortizable asset is a two step process. First, it is tested for impairment by comparing the undiscounted future cash flow projections with the carrying value of the asset. If upon comparison the carrying value exceeds the undiscounted cash flows then, under the second step, an impairment charge is recognized for the difference between carrying amount of the asset and the fair value thereof computed using a discounted cash flow approach. Under IFRS, there is only a one step process, wherein impairment is tested and recognized if upon comparison, the carrying value of the asset exceeds the discounted cash flows. The differential approach resulted in additional impairment being recorded.

Furthermore, under Previous GAAP a non-amortizable asset was tested for impairment at the asset level, whereas under IFRS the impairment testing was done at higher cash generating unit level, as it did not generate identifiable cash inflows independent from other assets. Impairment testing at such higher cash generating unit level under IFRS did not indicate any impairment and, accordingly, there was a reversal of impairment charge with respect to such non-amortizable assets.

The aforesaid differences have resulted in an increase in equity under IFRS by Rs.621,311, Rs.621,311 and Rs.99,315 as at April 1, 2007, June 30, 2007 and March 31, 2008, respectively, and a decrease in profit under IFRS by Rs.521,996 for the year ended March 31, 2008.

Furthermore, the consequential amortization impact of subsequent periods has been reversed. The impact of reversal of amortization resulted in an increase in equity under IFRS by Rs.4,070 and Rs.26,472 as at June 30, 2007 and March 31, 2008, respectively, and an increase in profit by Rs.4,070 and Rs.26,472 for the three months ended June 30, 2007 and the year ended March 31, 2008, respectively.

B. Employee benefits

Under Previous GAAP, in determining the liability in respect of employment benefits, the Company used discounting rates which were based on high-quality fixed-income investments prevalent at the reporting date. Under IFRS, the Company is required to use high quality corporate bond rates or, in the absence of a deep market for such bonds, the government bond rate is required to be used. The Company has used the government bond rates for actuarially valuing its defined benefit obligations, which resulted in an increase in the liability and, consequently, the net period benefit cost in each of the reporting periods.

Furthermore, until April 1, 2007, the Company used the corridor approach to record actuarial gains and losses under Previous GAAP. Upon adoption of IFRS, the Company elected to recognize all cumulative actuarial gains and losses in respect of defined benefit plans at April 1, 2007 (the date of transition) as an adjustment to opening retained earnings and has set the corridor to “zero”. Also, under Previous GAAP, the Company had recorded actuarial gains and losses as part of equity, which is not required under IFRS, thereby resulting in a reduced liability in the books with a corresponding positive impact on equity.

The aforesaid differences have resulted in a decrease in equity under IFRS by Rs.25,573 and Rs.67,985 as at April 1, 2007 and June 30, 2007, respectively, and increase in equity by Rs.16,413 as at March 31, 2008. Consequently, it also resulted in a decrease of profit under IFRS by Rs.42,412 and Rs.18,693 for the three months ended June 30, 2007 and year ended March 31, 2008, respectively.

C. Hedge accounting

Under Previous GAAP, for certain hedge relationships where the hedging instrument is an option, a terminal value approach to the assessment of effectiveness and measurement of ineffectiveness was adopted as permitted by Derivatives Implementation Group (“DIG”) Issue G20. Under IFRS, in the absence of any specific guidance that permits entities to adopt a terminal value approach for such relationships, hedge effectiveness is measured on the basis of intrinsic value and time value changes are excluded from these qualifying hedge relationships. Accordingly, for certain hedging relationships which were accounted as a cash flow hedge under Previous GAAP, the requirement of hedge accounting for the risk previously designated as the hedged risk are no longer met. Accordingly, under IFRS the fair value changes on certain options contracts are recognized in the income statement as compared to being recognized in equity under Previous GAAP.

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

4.

Explanation of transition to IFRS (continued)

c.

Reconciliations (continued)

The aforesaid differences have resulted in a decrease of profit under IFRS by Rs.25,490 for the year ended March 31, 2008.

D. Fringe benefit tax on employee share based payments

Indian tax regulations require the Company to pay a Fringe Benefit Tax upon the exercise of employee stock options. Under Previous GAAP, Fringe Benefit Tax is accrued upon the exercise of stock options. Under IFRS such Fringe Benefit Tax, if not recovered from employees, are accrued over the vesting period of the stock options. In the event, the Company decides to recover the related Fringe Benefit Tax from the employees exercising such options a reimbursement asset is recognized in the same period which offsets the accrual for the Fringe Benefit Tax.

The aforesaid differences have resulted in a decrease in equity under IFRS by Rs.61,147 and Rs.52,946 as of June 30, 2008 and March 31, 2008, respectively, and a decrease of profit under IFRS by Rs.61,147 and Rs.52,946 for the three months ended June 30, 2007 and the year ended March 31, 2008, respectively.

E. Tax adjustments

Intra-group transactions are eliminated upon consolidation. Under Previous GAAP, income taxes paid by the seller on intra-group profits in respect of assets that remain within the consolidated group, including the tax effect of any reversing temporary differences in the seller’s tax jurisdiction, are deferred. The amount is recognized in other assets or liabilities in the balance sheet until such time as the asset leaves the consolidated group, at which point the amount is reclassified to income tax expense. Under IFRS, any related deferred tax effects are measured based upon the tax rate of the purchaser. However, the tax effects are not eliminated unless the transacting entities are subject to the same tax rate.

Furthermore, the income tax expense recognized in each interim period under Previous GAAP is based on the best estimate of the weighted average effective income tax rate expected for the annual reporting period applied to the pre-tax income of the interim period. Under Previous GAAP, a consolidated Annual Effective Tax Rate is arrived at based upon projected tax expense and profit before taxes for each of the tax jurisdictions and then such consolidated Annual Effective Tax Rate is applied to consolidated profits for the quarter. Under IFRS, if different income tax rates apply to different tax jurisdictions, income tax expense is computed by applying the projected Annual Effective Tax Rate for each of the jurisdictions on the pre-tax income of the interim period for each of such jurisdictions, respectively.

The above differences in IFRS as compared to Previous GAAP, along with the tax impact of the adjustments as discussed above, have resulted in an increase in equity by Rs.453,957, Rs.313,711 and Rs.169,508 as of April 1, 2007, June 30, 2007 and March 31, 2008, respectively, and a decrease in profit by Rs.140,246 and Rs.257,015 for the three months ended June 30, 2007 and the year ended March 31, 2008, respectively.

F. Change in presentation of minority interest

Under IFRS, minority interest is reported as a separate item within equity. Previous GAAP requires minority interest to be presented separately from equity. Under IFRS, the minority’s share of net income is presented as an allocation of net income, whereas, under Previous GAAP, the minority’s share of net income is considered in determining net income.

The aforesaid differences have resulted in an increase of equity under IFRS by Rs.10,473 and Rs.7,450 as of April 1, 2007 and June 30, 2007, respectively, and a decrease of profit under IFRS by Rs.3,023 and Rs.10,473 for the three months ended June 30, 2007 and the year ended March 31, 2008, respectively.

iv. Explanation of material adjustments to the cash flow statement

Unlike Previous GAAP, under IFRS while bank overdrafts are disclosed as part of borrowings in the balance sheet, the same are reduced from cash and cash equivalents in preparation of the cash flows if they are repayable on demand and form an integral part of the Company’s cash management. There were bank overdrafts of Rs.526,030 as at April 1, 2007 and Rs.434,928 as at March 31, 2008 that were repayable on demand, and which formed an integral part of the Company’s cash management and were not considered as a reduction in cash and cash equivalents. Accordingly,

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

4.

Explanation of transition to IFRS (continued)

c.

Reconciliations (continued)

			the movement in such balances was classified as financing cash flows under Previous GAAP. These have now been reclassified under cash and cash equivalents under IFRS for the preparation of cash flow statements.
			In addition, restricted cash of Rs.606,159 as at April 1, 2007, Rs.20,223 as at June 30, 2007 and Rs.23,156 as at March 31, 2008 was not considered as cash and cash equivalents for the preparation of cash flow statements. Accordingly, movement in such balances was classified as investing cash flows under Previous GAAP. These have now been reclassified as cash and cash equivalents under IFRS.
			Furthermore, interest paid of Rs.363,254 and interest received of Rs.263,591 for the three months ended June 30, 2007 was classified as operating cash flows under Previous GAAP and have been reclassified as financing and investing cash flows, respectively, under IFRS. There were no other material differences between the cash flow statement presented under IFRS and the cash flow statement presented under Previous GAAP.

5.

Segment reporting

The Chief Operating Decision Maker (“CODM”) evaluates the Company’s performance and allocates resources based on an analysis of various performance indicators by operating segments. The operating segments reviewed by the CODM are as follows:

	•		Pharmaceutical Services and Active Ingredients (“PSAI”);
	•		Global Generics; and
	•		Proprietary Products

			Pharmaceutical Services and Active Ingredients. This segment includes active pharmaceutical ingredients and intermediaries, also known as active pharmaceutical products or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediaries become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes contract research services and the manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Thus, this segment was formed by aggregating our former active pharmaceutical ingredients and intermediates segment and custom pharmaceutical services segment.
			Global Generics. This segment consists of finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Company is transitioning to a new organization structure for this segment. While the resource allocation is done by the CODM at the global generics level, certain additional information (revenue and gross profit) with respect to the Company’s formulations and generics business continues to be reviewed by the CODM. Accordingly such further detailed information has also been included in this segment’s disclosure.
			Proprietary Products. This segment involves the discovery of new chemical entities for subsequent commercialization and out-licensing. It also involves the Company’s specialty pharmaceuticals business which is positioning to launch sales and marketing operations for in-licensed and co-developed dermatology products.
			The CODM reviews gross profit as the performance indicator for all three of the above segments. The Company does not review the total assets and liabilities for each segment. The property, plant and equipment used in the Company’s business, and the related depreciation and amortization expenses, are not fully identifiable with or allocable to individual reportable segments, as certain assets are used interchangeably between segments. The other assets are not specifically allocable to the segments. Consequently, management believes that it is not practicable to provide segment disclosures relating to total assets and liabilities since allocation among the various segments is not possible.

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

5.

Segment reporting (continued)

Information about segments:		For the three months ended June 30,
Segments		PSAI								Global Generics *								Proprietary Products								Others								Total
		2008				2007				2008				2007				2008				2007				2008				2007				2008				2007
Segment revenue (Note 1)		Rs.	4,613,286			Rs.	3,634,318			Rs.	10,286,939			Rs.	8,228,196			Rs.	38,483			Rs.	52,454			Rs.	99,095			Rs.	68,090			Rs.	15,037,803			Rs.	11,983,058
Gross profit		Rs.	1,499,218			Rs.	1,244,335			Rs.	5,941,815			Rs.	4,878,313			Rs.	30,833			Rs.	33,161			Rs.	22,471			Rs.	(86,931	)		Rs.	7,494,337			Rs.	6,068,878
Selling, general and administrative expenses																																			5,085,351				3,581,305
Research and development expenses																																			1,050,070				806,278
Other expense/(income), net																																			241,104				(82,681	)
Results from operating activities																																			1,117,812				1,763,976
Finance income, net																																			77,030				158,409
Share of profit/(loss) of equity accounted investees																																			297				(4,028	)
Profit before income tax																																			1,195,139				1,918,357
Income tax expense																																			(83,846	)			(321,715	)
Profit for the period																																		Rs.	1,111,293			Rs.	1,596,642

* Global Generics consists of:

Segments		Formulations								Generics								Global generics
		2008				2007				2008				2007				2008				2007
Segment revenue (Note 2)		Rs.	4,489,215			Rs.	4,051,195			Rs.	5,797,724			Rs.	4,177,001			Rs.	10,286,939			Rs.	8,228,196
Gross profit		Rs.	3,294,121			Rs.	2,906,054			Rs.	2,647,694			Rs.	1,972,259			Rs.	5,941,815			Rs.	4,878,313

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

6.

Business combinations

a. Acquisition of a unit of The Dow Chemical Company

On April 28, 2008, the Company, through its wholly owned subsidiary Dr. Reddy’s Laboratories (EU) Limited (“DRL EU”), acquired a unit of The Dow Chemical Company associated with its United Kingdom sites in Mirfield and Cambridge for a total cash consideration of Rs.1,301,899 (U.S.$32,137). The acquisition includes customer contracts, associated products, process technology, intellectual property, trademarks and the Dowpharma Small Molecules facilities located in Mirfield and Cambridge, United Kingdom. The Company also took over the existing work force as a part of the acquisition. The acquisition complements technology and experience synergies to the Company’s existing custom pharmaceutical business and gives access to a research and development team.

The Company has accounted for the acquisition under the purchase method in accordance with IFRS No. 3, “Business Combinations”. Accordingly, the financial results of the aforesaid acquired business for the period from April 29, 2008 to June 30, 2008 have been included in the unaudited condensed consolidated interim financial statements of the Company.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition:

		Recognized values on
Particulars		acquisition
Property, plant and equipment		Rs.	740,704
Intangible assets			800,883
Inventories			230,707
Non-current assets			45,923
Non-current liabilities			(115,565	)
Deferred tax liabilities, net			(250,350	)
Net identifiable assets and liabilities		Rs.	1,452,302
Negative goodwill on acquisition recognized in income statement			(150,403	)
Consideration paid in cash*		Rs.	1,301,899

As the acquisition involved a combination of a purchase of a unit of an existing entity and a purchase of certain identifiable assets, the carrying value of assets and liabilities before acquisition could not be determined in accordance with IFRS.

The estimated useful lives of intangibles acquired are as follows:

Customer related intangibles		4-11 years
Product related intangibles		6-13 years

The negative goodwill on acquisition is attributable mainly to lower amounts paid towards inventories and intangible assets in the acquired business. The acquired business contributed revenues of Rs.157,531 and, including negative goodwill, a profit of Rs.58,706 for the period from April 29, 2008 to June 30, 2008.

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

6.

Business combinations (continued)

b. Acquisition of BASF Corporation’s manufacturing facility in Shreveport, Louisiana, USA and related pharmaceutical contract manufacturing business.

On April 30, 2008, the Company acquired BASF Corporation’s pharmaceutical contract manufacturing business and its manufacturing facility in Shreveport, Louisiana, U.S.A. for a total cash consideration of Rs.1,639,276 (U.S.$40,466). The business involves contract manufacturing of generic prescription and over the counter products for branded and generic companies in the United States. This acquired business includes customer contracts, related ANDAs and NDAs, and trademarks, as well as the Shreveport manufacturing facility. The Company also took over the existing work force as a part of the acquisition.

The Company has accounted for the acquisition under the purchase method in accordance with IFRS No. 3, “Business Combinations”. Accordingly, the financial results of the aforesaid acquired business for the period from May 1, 2008 through June 30, 2008 have been included in the unaudited condensed consolidated interim financial statements of the Company.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition.

		Recognized values
Particulars		on acquisition
Property, plant and equipment		Rs.	755,607
Intangible assets			482,068
Inventories			248,198
Net identifiable assets and liabilities		Rs.	1,485,873
Goodwill on acquisition			153,403
Consideration paid, satisfied in cash*		Rs.	1,639,276

As the acquisition involved purchase of a unit of an existing entity with certain identifiable assets and liabilities, the carrying value of assets and liabilities before acquisition could not be determined in accordance with IFRS.

The estimated useful lives of intangibles acquired are as follows:

Customer related intangibles		4 - 9 years
Product related intangibles		9-10 years

Goodwill amounts to Rs.153,403 and is attributable mainly to the employee workforce acquired and the estimated values to be derived from the synergies for the Company due to cost savings. The acquired business contributed revenues of Rs.313,641 and net profit of Rs.2,434 for the period from May 1, 2008 to June 30, 2008.

c. Acquisition of Jet Generici SRL

On April 30, 2008, the Company acquired Jet Generici Srl, a company engaged in the sale of generic finished dosages in Italy for a total cash consideration of Rs.147,887 (Euro 2.34 million). The transaction was accounted as an acquisition of business under the purchase method in accordance with IFRS 3. The transaction resulted in the Company gaining an entry in the Italian market and resulted in goodwill of
Rs.162,356.

d. Pro-forma information

If the above acquisitions had taken effect at the beginning of the reporting period (i.e., April 1, 2007), the revenue, profit before tax and profit after tax of the Company for the applicable periods on a pro-forma basis would have been as below:

		Three months ended
		June 30, 2008				June 30, 2007
Revenue		Rs.	15,182,309			Rs.	12,712,666
Profit before tax			1,127,154				1,998,117
Profit after tax			1,072,964				1,644,951

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

7. Financial instruments

     Hedging of fluctuations in foreign currency

The Company is exposed to exchange rate risk which arises from its foreign exchange revenues, primarily in U.S. dollars, British Pounds and Euros, and foreign currency debt in U.S. dollars and Euros.

The Company uses forward exchange contracts and option contracts(derivatives) to mitigate its risk of changes in foreign currency exchange rates. Most of the forward exchange contracts and option contracts have maturities of less than one year after the balance sheet date. Where necessary, the forward exchange contracts are rolled over at maturity.

     Forecasted transactions

The Company classifies its option contracts hedging forecasted transactions as cash flow hedges and measures them at fair value. The fair value of option contracts used as hedges of forecasted transactions at June 30, 2008 was a liability of Rs.738,834 (as compared to a liability of Rs.10,064 at March 31, 2008), that were recognized as derivatives measured at fair value.

     Recognized assets and liabilities

Changes in the fair value of forward exchange contracts that economically hedge monetary assets and liabilities in foreign currencies and for which no hedge accounting is applied are recognized in profit or loss. Both the changes in fair value of the forward contracts and the foreign exchange gains and losses relating to the monetary items are recognized as part of “net financing costs”. The fair value of forward exchange contracts and option contracts used as economic hedges of monetary assets and liabilities in foreign currencies recognized in fair value derivatives was an asset of Rs.38,884 at June 30, 2008 (as compared to a liability of Rs.85,982 at March 31, 2008).

     Fair values

The carrying amount and fair value of financial instruments as at June 30, 2008 is a net liability of Rs.16,436,830 (as compared to a net liability of Rs.10,647,534 at March 31, 2008).

8.

Income taxes

     Current tax

Current tax expense for the interim periods is calculated based on the estimated average annual income tax applied on the pre tax income of the interim period.

Current tax for current and prior periods is classified as current liability to the extent that it is unpaid. Amounts paid in excess of amounts owed are classified as a current asset.

     Deferred tax

The amount of deferred tax provided is based on the expected movements of realization or settlement of the carrying amount of assets and liabilities, using the effective tax rate of the interim periods presented.

The primary components of the Company’s recognized deferred tax asset includes temporary differences related to expenses deferred for the tax purposes, operating and capital losses carried forward, provisions, impairment loss on receivables, impairment loss on investment and minimum alternate tax carry forward. The primary components of the Company’s deferred tax liabilities include temporary differences related to property, plant, equipment and intangible assets. Deferred tax expenses or benefits arise from the origination and reversal of temporary differences, the effect of change in tax rates and the benefit of tax losses recognized.

Current tax expense and deferred tax benefit recognized in the income statement for the three months ended June 30, 2008 is Rs.408,935 and Rs.325,089, respectively. For the three months ended June 30, 2007, there is a current tax expense of Rs.27,252 and a deferred tax expense of Rs.294,463, respectively. Total deferred tax benefit recognized directly in the equity was Rs.116,678 for the three months ended June 30, 2008. For the three months ended June 30, 2007 there was a deferred tax expense of Rs.9,122.

DR. REDDY’S LABORATORIES LIMITED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(in thousands, except share and per share data)

8. Income taxes (continued)

     Reconciliation of effective tax rate

     The reported income tax expense for the three months ended June 30, 2008 was calculated based on an estimated average annual income tax rate of 7.02%. For the three months ended June 30, 2007, the reported income tax expense was calculated based on an estimated average annual income tax rate of 16.77%. The difference between the estimated average annual effective income tax rate and the enacted tax rate is accounted for by a number of factors, including the effect of differences between Indian and foreign tax rates, expenses not deductible for tax purposes, income exempted from income taxes, effects of changes in tax laws and rates, and the effects of minimum alternate taxes.

9.

Property, plant and equipment

     Acquisitions and disposals

During the three months ended June 30, 2008, the Company acquired assets at an aggregate cost of Rs.2,838,655 (as compared to a cost of Rs.6,231,125 for the year ended March 31, 2008), including assets acquired through business combinations of Rs.1,496,374 (no assets were acquired through business combinations for the year ended March 31, 2008). Assets with a net book value of Rs.4,850 were disposed of during the three months ended June 30, 2008 (as compared to Rs.62,661 in assets disposed of for the year ended March 31, 2008), resulting in a gain on disposal of Rs.2,847 (as compared to a loss of Rs.7,629 for the year ended March 31, 2008). Depreciation expense for the three months ended June 30, 2008 was Rs.556,256 (as compared to Rs.393,154 for the three months ended June 30, 2007).

     Capital Commitments

As of March 31, 2008 and June 30, 2008, the Company was committed to spend approximately Rs.1,552,426 and Rs.1,069,525, respectively, under agreements to purchase property, plant and equipment. This amount is net of capital advances paid in respect of such purchases.

10. Goodwill

Goodwill arising upon acquisitions is not amortized but tested for impairment annually or more frequently if there are certain internal or external indicators.

The following table presents the changes in goodwill during the three months ended June 30, 2008 and the year ended March 31, 2008:

		Three months ended				Year ended
		June 30, 2008				March 31, 2008
Opening balance (1)		Rs.	17,179,231			Rs.	15,947,898
Goodwill arising upon purchase business combination			315,759				—
Impairment of goodwill (2)			—				(90,437	)
Effect of translation adjustments			1,128,424				1,321,770
Closing balance (1)		Rs.	18,623,414			Rs.	17,179,231

     Acquisitions and write-down of intangibles

During the three months ended June 30, 2008, the Company acquired other intangible assets at an aggregate cost of Rs.1,413,723 (as compared to a cost of Rs.211,377 for the year ended March 31, 2008), including assets acquired through business combinations of Rs.1,312,303 (no assets were acquired through business combinations for the year ended March 31, 2008). Amortization expenses for the three months ended June 30, 2008 was Rs.376,633 (as compared to amortization expenses of Rs.346,638 for the three months ended June 30, 2007).

During the year ended March 31, 2008, the Company tested the carrying value of betapharm related intangibles for impairment. This testing was triggered by certain adverse market conditions, such as decreases in market prices and an increasing trend in certain new type of rebates being negotiated with State Healthcare Insurance Fund (“SHI”) companies, and certain supply constraints. As a result of this review, the Company recorded a write-down of intangible assets of Rs.2,883,005 and adjusted the net carrying value of certain product related intangibles as of March 31, 2008.

Furthermore, during the year ended March 31, 2008, the Company also tested the carrying value of Litaphar related intangibles for impairment. This testing was triggered by certain adverse market conditions, such as decreases in sales and increases in costs of procurement. The fair values of these intangibles were determined based on discounted cash flow approach. As a result of this review, the Company recorded a write-down of intangible assets of Rs.127,506 and adjusted the net carrying value of product related intangibles as of March 31, 2008.

12. Inventories

Inventories consist of the following:

		As of
		June 30, 2008				March 31, 2008
Raw materials		Rs.	3,995,671			Rs.	3,226,016
Packing material, stores and spares			899,508				773,433
Work-in-process			2,545,983				2,345,849
Finished goods			5,601,684				4,787,532
		Rs.	13,042,846			Rs.	11,132,830

During the three months ended June 30, 2008 and June 30, 2007, the Company recorded an inventory write-down of Rs.37,120, and Rs.97,610 respectively, resulting from a decline in the net realizable value of certain finished goods and write down of certain raw materials. These amounts are included in the cost of revenues.

Cash and cash equivalents consist of:

		As of
		June 30, 2008				March 31, 2008
Cash balances		Rs.	159,088			Rs.	162,771
Balances with banks			3,564,841				7,258,670
Cash and cash equivalents on the balance sheet			3,723,929				7,421,441
Bank overdrafts used for cash management purposes			(895,802	)			(434,928	)
Cash and cash equivalents on the cash flow statement		Rs.	2,828,127			Rs.	6,986,513